By Hendry Santoso, Market Research and FS

Introduction

The pharmaceutical industry in Indonesia is more than just a commercial sector — it is a pillar of national resilience. It safeguards public health, supports industrial growth, and has the potential to transform Indonesia into a regional pharmaceutical powerhouse. In a country of over 280 million people, every tablet produced, every vaccine distributed, and every active ingredient sourced tells a story of science, policy, and economic ambition.

Over the past decade, Indonesia’s pharmaceutical landscape has evolved from a relatively fragmented network of local drug producers into a strategic sector intertwined with healthcare reform, industrial policy, and global supply chains. The introduction of the Social Security Agency on Health (BPJS Kesehatan) insurance program in 2014 triggered a surge in demand for affordable, quality medicines. At the same time, rising incomes and urban lifestyles spurred consumer appetite for over-the-counter health products, supplements, and wellness solutions.

The Indonesian pharmaceutical industry has emerged as the largest in ASEAN, with a market value projected to reach USD 11 billion in 2025, representing approximately 35% of the region’s total pharmaceutical expenditure. Supported by a population exceeding 278 million, a rising middle class, and the national health insurance scheme the industry benefits from a strong, structurally guaranteed domestic demand base. Today, the pharmaceutical sector is a crossroads of public necessity and private opportunity and a place where life-saving products meet billion-dollar market potential.

Market Trend and Size

Indonesia’s pharmaceutical market is no longer simply a BPJS procurement channel. It is evolving into a complex ecosystem where government health programs, private sector innovation, consumer demand, and regulatory reforms converge. Between 2020 and 2025, the sector not only recovered from the pandemic but also surpassed pre-pandemic growth rates, making Indonesia ASEAN’s third-largest pharmaceutical market by value.

Key Demand Drivers for Market Trend

Demographic Pressure

Indonesia’s population is projected to reach 280.5 million in 2025, making it the fourth largest globally. The 60+ age group is growing by 3.3% annually, while urbanization is set to rise from 57% in 2025 to 65% by 2035. Due to this rise, aging demographics will fuel demand for cardiovascular, oncology, and anti-diabetic drugs, while urban growth will boost premium OTC and e-health services.

Economic Lift

Economic fundamentals further reinforce market growth. GDP expanded by 5.12% year-on-year in Q2 2025, with per capita income reaching USD 5,800 nominal (USD 20,400 PPP). Healthcare spending, currently USD 46 billion (2024), is projected to rise to USD 58.1 billion by 2030, this economic growth expands private hospital networks and increases spending on branded drugs and health supplements.

Disease Burden Shift

The disease burden is also shifting toward non-communicable diseases (NCDs), which account for 73% of all deaths (WHO, 2024). Key prevalence rates include diabetes (10.9%), hypertension (~34%), and cancer (350,000 new cases annually), while infectious diseases such as tuberculosis and dengue remain significant. This burden drives demand for both acute and chronic care medicines, creating a resilient market base.

BPJS as a Market Anchor

The national health insurance program, BPJS, plays a pivotal role as a volume anchor, covering around 250 million people. It accounts for 55% of total drug consumption, procuring generics at prices 40–60% lower than retail, which guarantees volume stability but exerts margin pressure on manufacturers.

Segment Dynamics – Market Share

By Product

By Therapeutic Area

• Anti-infectives: 18% market
• Cardiovascular: 14%.
• Anti-diabetic: 10%.
•  Respiratory: 8%.

• Oncology: 5%.
• Others (incl. vitamins): 45%.

By Channel

• Hospital Pharmacies: ~50%
• Retail Pharmacies: ~35%
• E-pharmacy: ~15% share in 2024, expected to hit 20% by

Production Trend

The production landscape of Indonesia’s pharmaceutical industry has undergone notable shifts between 2020 and 2025. While domestic manufacturing capacity has expanded—particularly in finished-dose generics, vaccines, and select biologics—the country continues to face a structural imbalance between production and trade flows due to its over 90% reliance on imported active pharmaceutical ingredients (APIs).

The period also saw increased efforts to localize production:

• Commissioning of new API plants (e.g., Kimia Farma–Sungwun Pharmacopia).
• Vaccine manufacturing expansions at Bio Farma (e.g., IndoVac, HPV vaccine).
• Partnerships in biologics and chronic disease drugs (e.g., insulin collaboration with Novo Nordisk).

However, while finished product output has risen, trade data reveals a persistent pharmaceutical trade deficit, reflecting the gap between what Indonesia produces locally and what it must import—especially in high-value specialty drugs and upstream raw materials.

Production, Import, and Export Data 

Sources & Notes:

1. Production value is proxied using total domestic market value from BPS, IQVIA, Fitch Ratings, and GP Farmasi estimates, adjusted for inflation and exchange rates.
2. Imports (HS-30 “Pharmaceutical Products”) from UN Comtrade, CEIC, OEC, and Ministry of Trade; includes APIs and finished-dose products.
3. Exports (HS-30) from OEC, CEIC, and Ministry of Trade; primarily finished generics, some vaccines, OTC.

* 2024 and 2025 imports/exports are projections based on YTD trade data and historical patterns.

Interpreting the Trends

Domestic Production Growth

• 2020–2021 Surge: Production value jumped from USD 7.6B to USD 10.0B (+31.6%) due to pandemic-driven procurement, local vaccine filling, and OTC product spikes (vitamins, herbal remedies).
• 2022–2023 Stabilization: Growth moderated to ~4–5% annually as pandemic- related demand normalized but NCD-related demand (e.g., anti-diabetic, cardiovascular drugs) sustained output.
• 2024–2025 Outlook: Projected growth of 7–4.4%, driven by:
• Expansion in biologics (HPV vaccine, insulin production).
• Government incentives for local API
• Rising chronic disease prevalence fueling steady

Import Dynamics

Imports hovered between USD 2.1–2.5B annually, top in 2023 (+19% YoY) due to:

• Higher raw material (API) purchases as manufacturing
• Weak rupiah making imports costlier in nominal
• Drop in 2024 estimates (–16%) reflects:
• Post-pandemic stock
• Early impact of domestic API initiatives (though still small scale).

Export Performance

• Exports remain modest relative to imports—USD 6–0.8B annually.
• Growth is positive (+2–8% per year), led by:
• Vaccine shipments (Bio Farma) to ASEAN and
• Generic drug exports to the Philippines, India, and
• However, the export basket is still dominated by low-value generics, limiting its impact on narrowing the trade gap.

Persistent Trade Deficit

• The pharmaceutical trade deficit averages USD 25–1.77B annually.
• Even with projected narrowing to USD 25B by 2025, the gap remains substantial.
• Closing this gap requires:
• Scaling local API and intermediate
• Upgrading to high-value pharmaceutical exports (e.g., biologics, specialty

Major Pharmaceutical Companies in Indonesia

The Indonesian pharmaceutical landscape is a unique blend of state-led public health infrastructure and a competitive private sector that fuels innovation, consumer branding, and export growth. With more than 220 licensed pharmaceutical manufacturers registered with BPOM in 2024, the industry is both diverse in ownership and highly concentrated in output — the top 15 companies account for nearly three-quarters of total market value.

The market is broadly structured into three ownership categories:

• State-Owned Enterprises (SOEs): These form the backbone of the national health supply chain, producing generics for BPJS programs and vaccines for domestic and export use.
• Large Private Domestic Corporations: These players dominate branded generics, OTC medicines, and herbal products, leveraging strong consumer brands and extensive distribution.
• Foreign Multinationals & Joint Ventures (JVs): These focus on patented, high-value medicines, often importing finished products but increasingly localizing production of select therapeutic classes.

Leading Domestic Players

1. Kalbe Farma Tbk (KLBF)

Kalbe Farma is Indonesia’s largest pharmaceutical company, holding a 17–18% market share and maintaining an unmatched distribution network across the country. The company is publicly listed on the IDX and operates across branded generics, OTC products, nutritional supplements, and biologics. Kalbe’s major facilities are located in Bekasi, Cikarang, and Pulogadung, with an annual production capacity of approximately 10 billion solid-dose units and 200 million liquid-dose units. The company is actively investing in oncology biologics and insulin analogues to strengthen its innovation pipeline, while its export markets span ASEAN, Africa, and the Middle East.

2. Bio Farma (SOE)

Bio Farma is Indonesia’s sole national vaccine manufacturer, serving as a vital component of public health and a leading global exporter to over 150 countries. As the holding company for Kimia Farma and Indofarma, it plays a strategic role in the national pharmaceutical ecosystem. Its main facility in Bandung produces vaccines and serums, including the IndoVac COVID-19 vaccine with a capacity of 40 million doses per year, as well as HPV vaccines through technology transfer from MSD. Bio Farma is also committed to developing halal-compliant vaccines and supports the national immunization program.

3. Kimia Farma Tbk (KAEF)

Kimia Farma is a leading producer of generic medicines and OTC products, with a strategic edge in active pharmaceutical ingredient (API) production through its subsidiary Kimia Farma Sungwun Pharmacopia. The company operates solid-dose and liquid production facilities across Java, including an API plant in Cikarang with an annual capacity of 15–30 metric tons. It is also the only large-scale domestic API producer, strengthening Indonesia’s pharmaceutical self-sufficiency. Kimia Farma exports to ASEAN markets, leveraging its integrated manufacturing capabilities.

4. Dexa Medica

Dexa Medica is a privately owned pharmaceutical company recognized for its branded generics, in-licensed patented products, and herbal medicines. The company operates advanced GMP-certified plants specializing in solid-dose and sterile injectable products. Dexa Medica exports its products to ASEAN, Africa, and the Middle East, with popular brands including Lesichol and HerbaKOF.

5. Tempo Scan Pacific

Tempo Scan Pacific is a well-known name in OTC and consumer health products, combining FMCG distribution strength with pharmaceutical manufacturing expertise. The company owns leading brands such as Bodrex and Hemaviton, and operates production facilities in Jakarta and West Java. Tempo Scan has an extensive retail penetration, making it one of the strongest players in Indonesia’s consumer health market.

6. Soho Global Health

Soho Global Health dominates the pediatric and herbal supplement segment, with a focus on high-margin consumer health with well known brands such as Curcuma Plus, and Fitkom. Soho Global Health also exports to ASEAN countries, reinforcing its regional presence.

7. Sanbe Farma

Sanbe Farma specializes in sterile injectables, antibiotics, and ophthalmic products, making it a leading supplier for hospitals across Indonesia. The company has also expanded its footprint into ASEAN and the Middle East.

8. Ferron Par Pharmaceuticals

A subsidiary of Dexa Group, Ferron focuses on oncology and injectables; it has GMP certified sterile manufacturing, and export targets to Southeast Asia.

9. Konimex

A strong OTC and herbal medicine producer, with brands such as Konidin, and Prenagen. It has a strong brand recall and rural distribution.

10. Phapros Tbk

SOE-controlled and integrated into the BPJS supply chain, with capacity production of ~4B solid-dose units/year.

Operational Landscape of Domestic Players

Leading Foreign Multinational Companies

Pharmaceutical Companies’ Market Share

Potential Issues in Pharmaceutical Industries

The Indonesian pharmaceutical sector has experienced a resilient 7–9% CAGR in recent years, driven by demographic growth, universal healthcare (BPJS), and expanding middle- class demand. However, this upward trajectory is tempered by structural weaknesses that limit long-term competitiveness and could threaten supply chain stability during crises.

These issues are not isolated; they are interconnected — meaning a disruption in one area (e.g., API imports) can cascade into production delays, price surges, and even shortages in essential medicines.

API & Raw Material Dependency

Indonesia produces less than 10% of its API needs, relying on China (60%) and India (30%) for supply. Key imports include paracetamol, amoxicillin, metformin, atorvastatin, and oncology drugs like cisplatin. This dependence creates risks such as price volatility (paracetamol prices jumped 70% in 2020), supply delays during China’s lockdowns, and China-India trade dispute could choke Indonesia’s pharmaceutical pipeline. Case example: In 2020, Kimia Farma’s amoxicillin production stalled due to India’s export curbs, forcing BPOM to approve emergency imports of finished antibiotics.

Regulatory & Compliance Challenges

The Indonesian Food and Drug Authority (BPOM) registration process takes 18–24 months for a new chemical entity (NCE), 12–18 months for a generic drug, and 6–12 months for herbal or traditional medicines, and under Law No. 33/2014, all drugs are required to obtain Halal Certification in stages, with exemptions for emergency medicines. This involves sourcing halal-compliant gelatin, enzymes, and excipients, which are not always available locally.

As a result, multinational companies hesitate to fully localize production due to longer approval timelines, while domestic manufacturers risk losing their first-mover advantage when launching generics after patent expiry.

Price Control

BPJS enforces strict price caps to keep medicines affordable, but this significantly compresses margins. For example, paracetamol is capped at Rp120 per tablet, leaving manufacturers with only 5–8% profit.

Payment Delays

Reimbursement from BPJS often faces delays of 3–6 months, creating cash flow challenges for hospitals, distributors, and manufacturers across the supply chain.

Capacity & Technology Gaps

Large firms like Kalbe and Dexa run at 80% capacity, but many mid-tier players operate at 50–60%, raising costs. Advanced capabilities—HPAPIs, biosimilars, and lyophilized injectables—remain limited, with only Bio Farma and Kalbe Genexine investing in full biologics facilities.

Geographic Concentration & Distribution Bottlenecks

Over 70% of plants are in Java, making distribution to eastern Indonesia costly and slow. Cold-chain logistics can be three times more expensive outside Java, limiting access to biologics and vaccines.

Market Saturation

Generics face intense price wars with 200+ manufacturers competing for BPJS tenders. OTC and herbal products suffer brand dilution, and weak regulation gives informal producers an edge.

Talent & R&D Gap

R&D spending is just 1.5–2% of revenue versus 12–15% globally. Shortages of bioprocess engineers, clinical trial experts, and regulatory specialists persist, while brain drain to Singapore and Malaysia continues.

Global Compliance

Upgrading old plants to meet PIC/S GMP standards demands heavy CAPEX. Global buyers like UNICEF and WHO now require documented environmental compliance, adding cost pressure.

Strategic Implications

• National Security Concern: API reliance is a strategic
• Structural Reform Needed: BPOM process & BPJS pricing policies must be balanced between affordability & industry viability.
• Infrastructure Diversification: Incentivizing plants outside Java could reduce distribution bottlenecks.
• Innovation Push: Tax credits and R&D grants could close the gap with ASEAN peers.
• ESG Alignment: Early adoption of green pharmaceutical practices can improve export competitiveness.

ASEAN Benchmarking and Common Practices

Across ASEAN, different countries have taken very different paths in their own pharmaceutical industry:

Indonesia – Scale Without Full Self-Sufficiency

Indonesia commands the largest pharmaceutical market in ASEAN, representing roughly 30–35% of total ASEAN pharma spending.

Key drivers include:

• Demographics: A youthful yet aging mix — median age 9 — with increasing chronic disease prevalence (diabetes, hypertension).
• Universal Coverage: BPJS Kesehatan provides a stable baseline demand for
• Rising Middle Class: Fueling demand for branded drugs, specialty medicines, and supplements.

Thailand – The Regional Price Setter

Thailand’s pharmaceutical industry is smaller in market size (USD 6 billion) but punches above its weight in influence. The state-owned Government Pharmaceutical Organization (GPO):

• Produces high-volume generics for domestic use and
• Cuts prices by up to 94% compared to international brands, making Thailand a benchmark for affordable medicine in ASEAN.
• Leverages public sector purchasing power to keep domestic prices low and win competitive tenders abroad.

Strategic Advantage: Thailand’s combination of state-led production and competitive pricing has given it a reputation for cost leadership, which pressures higher-cost markets like Indonesia.

Malaysia – The Halal & Biotech Innovator

Malaysia’s USD 5 billion pharmaceutical market is built on dual positioning:

• Halal-certified manufacturing — appealing to the 1.9 billion global Muslim
• Biotech development — including biosimilars and niche biologics for

The Malaysian government actively supports R&D tax incentives, public-private research partnerships, and regulatory facilitation to shorten approval timelines.

Malaysia also scores higher than Indonesia on the Global Innovation Index, reflecting stronger infrastructure for product development.

Strategic Advantage: Malaysia’s ability to combine branding (halal) with innovation gives it a unique export proposition, especially to the Middle East and OIC markets.

Vietnam – The Contract Manufacturing Magnet

Vietnam’s market size (~USD 3.5 billion) is modest, but its manufacturing cost base is one of the lowest in ASEAN.

Key success factors:

• Industrial clustering: Concentrated pharma zones lower logistics and compliance costs.
• FDI attraction: Multinational companies use Vietnam as a regional manufacturing base for both ASEAN and global distribution.
• Regulatory evolution: While still less mature than Malaysia’s, Vietnam’s regulatory system is gradually aligning with international GMP standards.

Strategic Advantage: Vietnam is positioning itself as the ASEAN contract manufacturing hub, directly competing with Indonesia’s ambitions to expand exports.

The Philippines – Distribution Dominance Without Export Strength

The Philippines has a USD 4 billion market, largely driven by domestic consumption. Unilab — the country’s largest pharma company — commands ~20% market share, dominating OTC and ethical drug distribution. However:

• Limited R&D and biologics
• Minimal export
• Heavy reliance on imports for complex

Strategic Advantage: The Philippines excels at domestic retail penetration but lacks the export and innovation depth of its peers.

Comparative Insights – Strategic Themes Emerging

When we compare ASEAN’s approaches, four distinct competitive models emerge:

Scale-Driven Domestic Market – Indonesia, Philippines.

• • Pros: Large consumer base, stable
  • Cons: Risk of import dependency and price

Cost Leadership in Generics – Thailand, Vietnam.

• • Pros: Competitive pricing, export
  • Cons: Lower margins, heavy reliance on

Niche Branding & Innovation – Malaysia.

• • Pros: Premium positioning, export
  • Cons: Requires sustained R&D

Distribution Control – Philippines.

• • Pros: Strong market
  • Cons: Limited manufacturing and export

Implications for Indonesia

For Indonesia, the regional benchmarking reveals a strategic identity gap: It has scale, partial innovation (vaccines), and emerging halal positioning — but no clear regional dominance in cost, innovation, or branding.

To strengthen its ASEAN position, Indonesia must:

• Reduce API dependency to neutralize cost
• Develop a halal-certified pharma export program to rival
• Consider state-led or incentivized generics pricing to compete with Thailand’s GPO.
• Invest in regional manufacturing clusters to match Vietnam’s

Comparative Benchmark Overview

 Lessons from ASEAN Peers

Thailand – State-Led Cost Leadership

Thailand’s GPO proves that government-led manufacturing, when scaled, can control domestic prices and win regional tenders. Indonesia’s SOEs (Bio Farma, Kimia Farma) could emulate this by specializing in high-volume generics and essential APIs to reduce BPJS dependence on imports.

Malaysia – Halal & Biotech Branding

Malaysia’s biosimilar exports demonstrate the advantage of focusing on niche identity. Indonesia could leverage its halal compliance mandate not just for domestic regulation but also as a brand differentiator in Muslim-majority export markets.

Vietnam – Cost-Competitive Manufacturing

 Vietnam shows how lower labor costs, targeted tax incentives, and industrial clustering can attract contract manufacturing from big pharma. Indonesia’s challenge: replicating this without losing sight of compliance and quality standards.

SWOT Analysis – Indonesia Pharmaceutical Industry

Conclusion

The Strategic Crossroads

The Indonesian pharmaceutical industry is standing at an inflection point.

It is the largest pharmaceutical market in ASEAN and one of the top 15 in the world’s emerging economies, yet it is not the most competitive, innovative, or most cost-efficient player in the region.

Here’s the paradox:

• Demand is structurally guaranteed — 278 million people, an expanding middle class, and a universal health insurance scheme (BPJS Kesehatan) that creates stable base demand for generics.
• Supply competitiveness is structurally fragile — >90% API imports, higher drug prices than Malaysia and Thailand, and R&D spend less than half of regional leaders.

This duality means Indonesia’s market is a prize, but one that could increasingly benefit foreign suppliers and cheaper ASEAN exporters if local manufacturing and innovation don’t catch up.

From all prior data and trend analysis, three fundamental points emerge:

1.  Domestic Scale ≠ Competitive Advantage

Indonesia’s USD 11 billion-market size (2025 est.) is 30–35% of ASEAN total pharmaceutical spending. But without cost control, this scale benefits importers as much as domestic producers.

Example: In 2023, price differences for certain chronic disease medications between Indonesia and Malaysia were as high as +20–30% in favor of Malaysia — even when produced by similar companies.

2.  The Innovation Deficit Is a Strategic Risk

Malaysia spends ~4–5% of pharmaceutical revenue on R&D; Indonesia spends only 1.5–2%. This is not just a statistic — it means:

• Fewer locally developed
• Limited entry into biosimilars and high-margin specialty
• Continued reliance on formulation-based manufacturing, which captures less

3.  ASEAN Peers Are Defining Their Niche — Indonesia Hasn’t

• Thailand: Cost leader in high-volume generics via GPO — undercuts prices
• Malaysia: Halal biosimilar exporter with established OIC market
• Vietnam: Contract manufacturing hub with lower production
• Philippines: Distribution dominance, though limited

Indonesia’s competitive “identity” remains fragmented — a large domestic market without a signature exportable advantage.

  Strategic Imperatives for Indonesia

1.Build API Sovereignty

• Establish dedicated API industrial parks with fiscal
• Prioritize 10–15 critical APIs (antibiotics, cardiovascular, diabetes, antivirals) that represent >60% of BPJS drug spend.
• Set a 2030 goal: Reduce API imports from 90% to below 60%.

2.  Own the Halal Pharma Position

• Launch a “Halal Pharma Indonesia” initiative targeting OIC export
• Integrate halal branding into international marketing, not just local
• Position Indonesia as the largest halal-certified pharmaceutical exporter in ASEAN by 2032.

3.  Move Up the Value Chain into Biologics

• Repurpose COVID vaccine facilities for biosimilar insulin, oncology injectable, and monoclonal antibodies.
• Offer fast-track regulatory approvals for domestic
• Provide co-investment schemes with global pharma for technology

4.  Decentralize Manufacturing

• Build pharma industrial clusters in Sumatra, Kalimantan, Sulawesi to:
• Reduce logistics costs by up to 15%.
• Increase drug access in Eastern
• Mitigate disaster risk from Java-centric

5.  Compete Aggressively on Regional Pricing

• Create a state-backed generics division modeled on Thailand’s GPO to secure BPJS supply at controlled costs.
• Target ASEAN joint procurement tenders for essential

Forward Outlook – Two Scenarios

Scenario A – Decisive Reform (Optimistic)

• API dependency down to 60% by
• Export share rises from <5% today to 15–18%.
• Halal-certified exports penetrate Middle East and
• Indonesia becomes ASEAN’s leading halal pharma exporter and a biologics

Scenario B – Status Quo (Pessimistic)

• API imports remain above 85%.
• Export share stays below 7%.
• Thailand and Malaysia capture more ASEAN tenders, eroding Indonesia’s regional influence.
• Domestic producers face margin squeeze from BPJS pricing pressures and import competition.

Closing View 

Indonesia has four unique strengths:

• Massive domestic market
• Universal health coverage ensuring baseline
• Halal certification ecosystem
• Vaccine manufacturing expertise unmatched in ASEAN

But strengths alone don’t win markets — they need sharp positioning. If Indonesia continues as a generalist in a region full of specialists, it risks losing both cost competitiveness and export relevance. The choice ahead is clear: Define a niche, build supply sovereignty, and leverage scale into strategic dominance — or remain the biggest buyer in ASEAN, not its biggest seller. 

   Conclusion Table – Key Findings & Actions

Sources

• Skylight Analytics Hub
• Badan Pusat Statistik (BPS) – Pertumbuhan Ekonomi Indonesia Triwulanan 2020– 2025, https://www.bps.go.id
• Kementerian Kesehatan RI (Kemenkes) – Profil Kesehatan Indonesia 2020–2024
• Annual reports on national health indicators, disease burden, and pharmaceutical consumption trends.
• BPJS Kesehatan – Statistik Pengelolaan Program JKN (2020–2025)
• Key reference for national health insurance coverage and drug utilization
• Badan Pengawas Obat dan Makanan (BPOM) – Laporan Tahunan Industri Farmasi (2020–2024)
• Kementerian Perindustrian RI (Kemenperin) – Rencana Induk Pengembangan Industri Nasional (RIPIN) & Peta Jalan Industri Farmasi
• IQVIA – Indonesia Pharmaceutical Market Overview 2020–2025
• Frost & Sullivan – ASEAN Pharmaceutical Industry Outlook (2023 Edition)
• OECD Health Policy Studies – Pharmaceutical Pricing Policies in a Global Context(2023)
• World Health Organization (WHO) – Global Report on Access to Medicines (2022)
• UN Comtrade Database – Pharmaceutical Trade Statistics (HS Code 30) for Indonesia and ASEAN (2020–2025)
• Pratama, A. & Hidayat, R. (2023). Strategic Analysis of Indonesia’s Pharmaceutical Industry in the ASEAN Context. Journal of Industrial Policy & Economics, 15(2),45–68.
• Sutanto, et al. (2024). Halal Pharmaceutical Certification and Global Market Potential. Asian Business & Trade Review, Vol. 22(1), pp. 99–124.
• Widjaja, (2022). Supply Chain Risks in Emerging Market Pharmaceuticals. Global Health Economics Review, Vol. 8(3), pp. 210–235.
• PT Kalbe Farma Tbk – Annual Report 2020–2024
• Bio Farma – Corporate Profile & Vaccine Production Report (2023)
• Thai Government Pharmaceutical Organization (GPO) – Annual Report 2023
• Malaysian Investment Development Authority (MIDA) – Halal Pharmaceutical Industry Report 2023
• Vietnam Ministry of Industry and Trade – Pharmaceutical Sector Overview 2023

Disclaimer

The content on this platform (“Platform”) is proprietary to Skylight, protected under copyright and intellectual property laws, and cannot be reproduced or used without written authorization. The insights shared are for informational purposes only, do not constitute professional advice, and may not reflect the latest industry developments. Skylight and its contributors disclaim all liability for actions taken based on the content and do not guarantee specific outcomes from past insights or case studies. Use of the Platform does not establish any contractual or advisory relationship with Skylight. By accessing this Platform, you agree to these terms. © 2025 Skylight Strategic Indonesia. All rights reserved.